Course and Correlates of Stigma in Patients on Opioid Agonist Treatment: A Prospective Study from an Outpatient Treatment Program in India

被引:1
|
作者
Ghosh, Abhishek [1 ]
Roub, Fazle [1 ]
Pillai, Renjith R. [1 ]
Mahintamani, Tathagata [1 ]
Basu, Debasish [1 ]
Subodh, B. N. [1 ]
Mattoo, S. K. [1 ]
机构
[1] Postgrad Inst Med Educ & Res, Drug Deaddict & Treatment Ctr, Dept Psychiat, Sect 12, Chandigarh 160012, India
关键词
Buprenorphine; enacted stigma; internalized stigma; opioid dependence; quality of life; SUBSTANCE USE DISORDERS; INTERNALIZED STIGMA; MENTAL-ILLNESS; SELF-STIGMA; INDIVIDUALS; QUALITY; SCALE; ABUSE; MODEL; LIFE;
D O I
10.1177/02537176211012103
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background: Individuals with opioid dependence experience stigma and discrimination. Stigma can potentially reduce treatment-seeking and negatively affect treatment outcomes. We aimed to study the course of stigma and its correlates among patients receiving opioid agonist treatment (OAT). Methods: We recruited 51 subjects (aged between 18 and 45 years) registered in the OAT clinic from February to September 2019. We excluded subjects dependent on alcohol and other drugs (except for cannabis and tobacco), with severe mental illness, intellectual disability, and organic brain disease. We assessed the internalized and enacted stigma and quality of life at the treatment entry and after 3 months. Relationship of stigma with quality of life, socio-demographic, and other clinical variables were examined at the treatment entry. Results: Mean age of the subjects was 26.7 (+/- 5) years. At the end of three months, 33 (64.7%) patients were retained in the treatment. Internalized stigma correlated negatively with the social and environmental domains of quality of life. The strength of the correlations was modest. No significant correlation was found between demographic and clinical variables and internalized stigma and enacted stigma scores. Both internalized and enacted stigma scores reduced significantly at 3 months follow-up. The significance levels were retained even after controlling for the baseline quality of life scores. Stigma at the treatment entry did not predict early dropout. Conclusion: Despite higher severity at the treatment entry, the level of internalized and enacted stigma reduced significantly within three months of an outpatient-based OAT program.
引用
收藏
页码:246 / 252
页数:7
相关论文
共 50 条
  • [21] Integrated telemedicine-based treatment for hepatitis C at an opioid agonist treatment program
    Brown, Lawrence S.
    Talal, Andrew
    Andrews, Phyllis
    Mcleod, Anthony
    Zeremski, Marija
    Chen, Yang
    Sylvester, Clewert
    DRUG AND ALCOHOL DEPENDENCE, 2017, 171 : E27 - E28
  • [22] Brief Interventions for Harmful Alcohol Use in Opioid-dependent Patients on Maintenance Treatment With Buprenorphine: A Prospective Study From India
    Varshney, Mohit
    Ambekar, Atul
    Lal, Rakesh
    Yadav, Deepak
    Rao, Ravindra
    Mishra, Ashwani
    ADDICTIVE DISORDERS & THEIR TREATMENT, 2016, 15 (03): : 129 - 135
  • [23] Changing Pattern of Opioid Users Attending an Opioid Agonist Treatment Clinic in North India
    Bhat, Fazle R.
    Rather, Yasir H.
    Rasool, Ubaid
    JOURNAL OF NEUROSCIENCES IN RURAL PRACTICE, 2022, 13 (02) : 176 - 180
  • [24] Neurocognitive performance of patients undergoing intravenous versus oral opioid agonist treatment: a prospective multicenter study on three-month treatment effects
    Chamakalayil, Sunsha
    Stohler, Rudolf
    Moldovanyi, Andreas
    Gerber, Markus
    Brand, Serge
    Dursteler, Kenneth M.
    FRONTIERS IN PSYCHIATRY, 2024, 15
  • [25] Opioid Agonist Treatment for Opioid Use Disorder patients in Central Asia
    Michels, Ingo Ilja
    Stover, Heino
    Aizberg, Oleg
    Boltaev, Azizbek
    HEROIN ADDICTION AND RELATED CLINICAL PROBLEMS, 2021, 23 (01) : 33 - 46
  • [26] Induction to Methadone 80 mg in the First Week of Treatment of Patients Who Use Fentanyl: A Case Series From an Outpatient Opioid Treatment Program
    Steiger, Scott
    Mccuistian, Caravella
    Suen, Leslie W.
    Shapiro, Brad
    Tompkins, D. Andrew
    Bazazi, Alexander R.
    JOURNAL OF ADDICTION MEDICINE, 2024, 18 (05) : 580 - 585
  • [27] Virtual opioid agonist treatment: Alberta’s virtual opioid dependency program and outcomes
    Nathaniel Day
    Maureen Wass
    Kelly Smith
    Addiction Science & Clinical Practice, 17
  • [28] Virtual opioid agonist treatment: Alberta's virtual opioid dependency program and outcomes
    Day, Nathaniel
    Wass, Maureen
    Smith, Kelly
    ADDICTION SCIENCE & CLINICAL PRACTICE, 2022, 17 (01)
  • [29] Opioid Agonist Treatment for Patients With Dependence on Prescription Opioids
    Nielsen, Suzanne
    Larance, Briony
    Lintzeris, Nicholas
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 317 (09): : 967 - 968
  • [30] Co-Located hepatitis C virus infection treatment within an opioid treatment program promotes opioid agonist treatment retention
    Severe, Brooke
    Tetrault, Jeanette M.
    Madden, Lynn
    Heimer, Robert
    DRUG AND ALCOHOL DEPENDENCE, 2020, 213